{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-254135","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2023-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.093994+00:00","generated_at":"2026-06-10T01:42:18.823636+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PMV Pharma to present updated Phase 1 PC14586 data at AACR-NCI-EORTC; KOL webinar planned","bullets":["Updated Phase 1 data cutoff Sep 5, 2023; abstract with May 1 cutoff published.","Poster session October 12, 2023 12:30-4:00 PM ET at AACR-NCI-EORTC conference.","PC14586 targets p53 Y220C mutation in advanced solid tumors; PYNNACLE study ongoing.","KOL webinar October 12 at 4:00 PM ET with regulatory update included.","Data also discussed in Chemistry in Cancer Research Town Hall and Concurrent Session 8."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-254135","json":"https://secwatch.observer/filing/0001193125-23-254135.json","markdown":"https://secwatch.observer/filing/0001193125-23-254135.md","text":"https://secwatch.observer/filing/0001193125-23-254135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000119312523254135/0001193125-23-254135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000119312523254135/d516537d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T01:42:18.823636+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}